Welcome to AstraZeneca United States

vn破解版苹果


vn破解版苹果


vn破解版苹果

Researching antibodies to target COVID-19

AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies. Harnessing internal expertise and via new collaborations, the aim is to identify monoclonal antibodies that have the potential to recognise, bind to and neutralise the SARS-CoV-2 virus, to decrease the impact of COVID-19.

View press release


vn破解版苹果

Designation based on unprecedented results from the Phase III ADAURA trial where TAGRISSO reduced the risk of disease recurrence or death by c. 80%

vn破解版苹果

FARXIGA significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type 2 diabetes

vn破解版苹果

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies

vn破解版苹果


vn破解版苹果

vn破解版苹果

vn破解版苹果

兔子 turbo 加速器

The Path Forward, Evolving the Current Healthcare System

Important Discoveries in Asthma